France
· Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 236.27 million. The enterprise value is 211.55 million.
| Market Cap | 236.27M |
| Enterprise Value | 211.55M |
Important Dates
The next estimated earnings date is Friday, September 13, 2024.
| Earnings Date | Sep 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 6.23% in one year.
| Shares Outstanding | 47.40M |
| Shares Change (YoY) | +6.23% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 2.70% |
| Owned by Institutions (%) | 21.45% |
| Float | 22.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.08 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.33 |
| EV / Sales | 5.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.52 |
Financial Position
The company has a current ratio of 1.75
| Current Ratio | 1.75 |
| Quick Ratio | 1.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.95 |
| Interest Coverage | -3.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.72% |
| Return on Capital (ROIC) | -40.48% |
| Revenue Per Employee | 354,980 |
| Profits Per Employee | -389,216 |
| Employee Count | 102 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.38% in the last 52 weeks. The beta is 1.29, so Nanobiotix's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -42.38% |
| 50-Day Moving Average | 4.69 |
| 200-Day Moving Average | 5.64 |
| Relative Strength Index (RSI) | 58.14 |
| Average Volume (20 Days) | 64,135 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 36.21 million and -39.70 million in losses. Loss per share was -1.08.
| Revenue | 36.21M |
| Gross Profit | 36.21M |
| Operating Income | -24.24M |
| Pretax Income | -39.58M |
| Net Income | -39.70M |
| EBITDA | -23.69M |
| EBIT | -24.24M |
| Loss Per Share | -1.08 |
Balance Sheet
The company has 75.28 million in cash and 50.57 million in debt, giving a net cash position of 24.72 million or 0.52 per share.
| Cash & Cash Equivalents | 75.28M |
| Total Debt | 50.57M |
| Net Cash | 24.72M |
| Net Cash Per Share | 0.52 |
| Equity (Book Value) | -1.84M |
| Book Value Per Share | -0.04 |
| Working Capital | 37.47M |
Cash Flow
In the last 12 months, operating cash flow was -12.48 million and capital expenditures -328,000, giving a free cash flow of -12.80 million.
| Operating Cash Flow | -12.48M |
| Capital Expenditures | -328,000 |
| Free Cash Flow | -12.80M |
| FCF Per Share | -0.27 |
Margins
Gross margin is 100.00%, with operating and profit margins of -66.94% and -109.64%.
| Gross Margin | 100.00% |
| Operating Margin | -66.94% |
| Pretax Margin | -109.31% |
| Profit Margin | -109.64% |
| EBITDA Margin | -65.42% |
| EBIT Margin | -66.94% |
| FCF Margin | -35.36% |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.23% |
| Shareholder Yield | -6.23% |
| Earnings Yield | -21.67% |
| FCF Yield | -5.42% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |